Veeva Systems Inc. $VEEV Shares Bought by Allworth Financial LP

Allworth Financial LP grew its position in Veeva Systems Inc. (NYSE:VEEV) by 1,070.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,934 shares of the technology company’s stock after purchasing an additional 9,085 shares during the quarter. Allworth Financial LP’s holdings in Veeva Systems were worth $2,861,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in VEEV. Mutual of America Capital Management LLC raised its stake in Veeva Systems by 13.8% in the first quarter. Mutual of America Capital Management LLC now owns 3,577 shares of the technology company’s stock valued at $829,000 after buying an additional 433 shares during the last quarter. CWM LLC increased its holdings in shares of Veeva Systems by 8.3% during the first quarter. CWM LLC now owns 8,785 shares of the technology company’s stock valued at $2,035,000 after acquiring an additional 676 shares in the last quarter. Edgestream Partners L.P. purchased a new position in shares of Veeva Systems in the 1st quarter valued at approximately $4,563,000. Signaturefd LLC boosted its stake in Veeva Systems by 22.1% in the 1st quarter. Signaturefd LLC now owns 1,507 shares of the technology company’s stock worth $349,000 after purchasing an additional 273 shares in the last quarter. Finally, Dakota Wealth Management grew its position in Veeva Systems by 5.6% during the 1st quarter. Dakota Wealth Management now owns 7,391 shares of the technology company’s stock worth $1,712,000 after purchasing an additional 393 shares during the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Veeva Systems Stock Down 0.7%

NYSE:VEEV opened at $297.11 on Thursday. Veeva Systems Inc. has a 52 week low of $201.54 and a 52 week high of $310.50. The stock’s 50-day moving average price is $288.05 and its 200-day moving average price is $276.78. The stock has a market capitalization of $48.70 billion, a PE ratio of 61.01, a price-to-earnings-growth ratio of 2.22 and a beta of 0.98.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The business had revenue of $789.08 million for the quarter, compared to analysts’ expectations of $768.49 million. During the same quarter in the prior year, the company posted $1.62 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Sell-side analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Insider Activity at Veeva Systems

In related news, insider Thomas D. Schwenger sold 3,350 shares of Veeva Systems stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total value of $1,005,134.00. Following the sale, the insider owned 23,773 shares of the company’s stock, valued at approximately $7,132,850.92. This trade represents a 12.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the company’s stock in a transaction on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the transaction, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. This represents a 19.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 24,665 shares of company stock valued at $7,438,000. 10.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on VEEV shares. Citigroup upped their target price on Veeva Systems from $329.00 to $349.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Wall Street Zen lowered Veeva Systems from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Evercore ISI raised their price objective on Veeva Systems from $285.00 to $295.00 and gave the stock an “in-line” rating in a research note on Thursday, August 28th. UBS Group upped their target price on Veeva Systems from $285.00 to $310.00 and gave the company a “neutral” rating in a research report on Thursday, August 28th. Finally, Stifel Nicolaus raised their price target on shares of Veeva Systems from $295.00 to $320.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Seventeen research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Veeva Systems presently has an average rating of “Moderate Buy” and a consensus target price of $307.58.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.